Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

Stockholders' Equity - Additional Information (Details)		1 Months Ended		3 Months Ended
Stockholders' Equity - Additional Information (Details)	Jan. 01, 2023 $ / shares shares	Apr. 30, 2023 USD ($) $ / shares shares	Feb. 28, 2023 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) Vote multiplier $ / shares shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 $ / shares shares	Nov. 03, 2022 $ / shares shares	Nov. 02, 2022 shares	Nov. 30, 2020 USD ($)	Mar. 17, 2015
Stockholders' Equity
Common stock, shares authorized				50,000,000		50,000,000	50,000,000	13,500,000
Common stock, par value (in dollars per share) \| $ / shares				$ 0.0001		$ 0.0001	$ 0.0001
Common stock, shares outstanding				13,201,070		9,586,683
Number of votes per share \| Vote				1
Multiplier to calculate voting rights per class A common share \| multiplier				1.1
Number of non assessable shares issued upon conversion				1
Shelf registration statement, maximum authorized securities \| $									$ 100,000,000
Commissions and other transaction costs \| $			$ 7,500,000
Issuance of common shares - Founders agreement \| $				$ 156,000	$ 196,000
Shelf registration statement remaining authorized securities \| $				150,000,000
Equity Method Investment, Annual Equity Fee, Percentage										2.50%
Net proceeds from offering \| $		$ 5,500,000
Pre-Funded Warrants
Stockholders' Equity
Number of warrants issued			248,572
Exercise price \| $ / shares			$ 5.2499
Series A warrants
Stockholders' Equity
Number of shares issued for warrants		1,700,000
Exercise price \| $ / shares		$ 3.35
Expiration term		5 years
Series B warrants
Stockholders' Equity
Number of shares issued for warrants		1,700,000
Exercise price \| $ / shares		$ 3.35
Expiration term		18 months
Non-vested restricted stock
Stockholders' Equity
Total unrecognized compensation cost related to non-vested \| $				$ 4,000,000.0
Weighted average period (in years)				2 years 1 month 6 days
Performance Shares
Stockholders' Equity
Restricted stock outstanding non-vested				203,133
2015 Incentive Plan
Stockholders' Equity
Number of shares available for issuance authorized				3,000,000
Plans expires (in years)				10 years
Shares are available for issuance				706,964
At the market offering (ATM)
Stockholders' Equity
Purchase price per share \| $ / shares	$ 2.5		$ 5.25
Commissions and other transaction costs \| $			$ 800,000
Number of shares issued	368,907		1,180,000
Exercise price \| $ / shares			$ 5.00
February 2023 Direct Offering
Stockholders' Equity
Purchase price per share \| $ / shares			$ 5.25
Number of shares issued			1,180,000
Number of warrants issued			248,572
Exercise price \| $ / shares			$ 5.2499
Net proceeds from offering \| $			$ 6,700,000
February 2023 Direct Offering \| Pre-Funded Warrants
Stockholders' Equity
Number of warrants issued			248,572
February 2023 Direct Offering \| Series A warrants
Stockholders' Equity
Number of shares issued for warrants			1,428,572
Exercise price \| $ / shares			$ 5.00
Expiration term			5 years
February 2023 Direct Offering \| Series B warrants
Stockholders' Equity
Number of shares issued for warrants			1,428,572
Exercise price \| $ / shares			$ 5.00
Expiration term			18 months
Fortress
Stockholders' Equity
Issuance of common shares - Founders agreement \| $			$ 156,000
Shelf registration statement remaining authorized securities \| $				$ 14,800,000
Equity Method Investment, Annual Equity Fee, Percentage	2.50%			2.50%
Number of shares issued	368,907		35,714
Agent
Stockholders' Equity
Commission rate									3.00%
Common Class A
Stockholders' Equity
Common stock, shares authorized							700,000
Common stock, shares outstanding				700,000		700,000